Skip to main content

Advertisement

SpringerLink
Log in

Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort

  • Original paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Objective

Inflammation plays an important role in lung carcinogenesis. Epidemiologic studies have reported inverse associations of non-steroidal anti-inflammatory drug (NSAID) use and lung cancer risk. Previously, we found that ever use of glucosamine and chondroitin, which have anti-inflammatory properties, were inversely associated with lung cancer risk. After an additional year of follow-up, we further examined the association including frequency/duration of use, interaction with factors associated with inflammation, and lung cancer histology.

Methods

Participants were members of the VITamins And Lifestyle cohort. Adults, aged 50–76 years, who were residents of western Washington State, completed a baseline questionnaire in 2000–2002 (n = 76,904). Participants were queried on their use of glucosamine and chondroitin, over the 10 years prior to baseline, and categorized as nonuser, low use <4 days/week or <3 years, or high use ≥4 days/week and ≥3 years. Lung cancer cases (n = 808) were ascertained through linkage to the Surveillance, Epidemiology, and End Results cancer registry.

Results

High 10-year use of glucosamine [hazard ratio (HR), 0.77; 95% CI: 0.56–1.07; p trend = 0.04] but not chondroitin was associated with a reduction in lung cancer risk. The association with glucosamine was limited to adenocarcinoma (HR, 0.49; 95% CI: 0.27–0.90; p trend <0.01) and was not modified by NSAID use or smoking status.

Conclusions

Our results for glucosamine use are similar to the prior human studies of NSAID use and lung cancer, both in magnitude and the limitation of the association to adenocarcinoma. Unlike NSAIDs, glucosamine has no known adverse effects. Although confirmatory studies are needed, glucosamine is an attractive candidate for lung cancer chemoprevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM (2008) Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66(3):208–217

    Article  PubMed  Google Scholar 

  2. Khuder SA, Herial NA, Mutgi AB, Federman DJ (2005) Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 127(3):748–754

    Article  PubMed  Google Scholar 

  3. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW (2010) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. Epub 7 Dec 2010

  4. Bonovas S, Tsantes A, Drosos T, Sitaras NM (2008) Cancer chemoprevention: a summary of the current evidence. Anticancer Res 28(3B):1857–1866

    PubMed  CAS  Google Scholar 

  5. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM et al (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117(16):2104–2113

    Article  PubMed  CAS  Google Scholar 

  6. Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340(24):1888–1899

    Article  PubMed  CAS  Google Scholar 

  7. Satia JA, Littman A, Slatore CG, Galanko JA, White E (2009) Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev 18(5):1419–1428

    Article  PubMed  CAS  Google Scholar 

  8. Iovu M, Dumais G, du Souich P (2008) Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis and cartilage/OARS. Osteoarthritis Res Soc 16(Suppl 3):S14–S18

    Article  Google Scholar 

  9. Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J et al (2003) Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis and cartilage/OARS. Osteoarthritis Res Soc 11(4):290–298

    Article  CAS  Google Scholar 

  10. Chan PS, Caron JP, Orth MW (2006) Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J Rheumatol 33(7):1329–1340

    PubMed  CAS  Google Scholar 

  11. Zou L, Yang S, Champattanachai V, Hu S, Chaudry IH, Marchase RB et al (2009) Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-{kappa}B signaling. Am J Physiol Heart Circ Physiol 296(2):H515–H523

    Article  PubMed  CAS  Google Scholar 

  12. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST (2008) Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300(24):2867–2878

    Article  PubMed  CAS  Google Scholar 

  13. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62(12):1145–1155

    Article  PubMed  CAS  Google Scholar 

  14. White E, Patterson RE, Kristal AR, Thornquist M, King I, Shattuck AL et al (2004) VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol 159(1):83–93

    Article  PubMed  Google Scholar 

  15. Satia-Abouta J, Patterson RE, King IB, Stratton KL, Shattuck AL, Kristal AR et al (2003) Reliability and validity of self-report of vitamin and mineral supplement use in the vitamins and lifestyle study. Am J Epidemiol 157(10):944–954

    Article  PubMed  Google Scholar 

  16. Field RW, Smith BJ, Platz CE, Robinson RA, Neuberger JS, Brus CP et al (2004) Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 96(14):1105–1107

    Article  PubMed  CAS  Google Scholar 

  17. Slatore CG, Littman AJ, Au DH, Satia JA, White E (2008) Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. Am J Respir Crit Care Med 177(5):524–530

    Article  PubMed  CAS  Google Scholar 

  18. Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299(6710):1247–1250

    Article  PubMed  CAS  Google Scholar 

  19. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE (2002) Aspirin and lung cancer in women. Br J Cancer 87(1):49–53

    Article  PubMed  CAS  Google Scholar 

  20. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88(5):684–688

    Article  PubMed  CAS  Google Scholar 

  21. Holick CN, Michaud DS, Leitzmann MF, Willett WC, Giovannucci E (2003) Aspirin use and lung cancer in men. Br J Cancer 89(9):1705–1708

    Article  PubMed  CAS  Google Scholar 

  22. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK et al (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88(11):1687–1692

    Article  PubMed  CAS  Google Scholar 

  23. Skriver MV, Norgaard M, Poulsen AH, Friis S, Harving H, Fryzek J et al (2005) Use of nonaspirin NSAIDs and risk of lung cancer. Int J Cancer 117(5):873–876

    Article  PubMed  CAS  Google Scholar 

  24. Hayes JH, Anderson KE, Folsom AR (2006) Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 15(11):2226–2231

    Article  PubMed  CAS  Google Scholar 

  25. Feskanich D, Bain C, Chan AT, Pandeya N, Speizer FE, Colditz GA (2007) Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. Br J Cancer 97(9):1295–1299

    Article  PubMed  CAS  Google Scholar 

  26. Hernandez-Diaz S, Garcia Rodriguez LA (2007) Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer 120(7):1565–1572

    Article  PubMed  CAS  Google Scholar 

  27. Siemes C, Visser LE, Coebergh JW, Hofman A, Uitterlinden AG, Stricker BH (2008) Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype. Curr Cancer Drug Targets 8(8):753–764

    Article  PubMed  CAS  Google Scholar 

  28. Slatore CG, Au DH, Littman AJ, Satia JA, White E (2009) Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 18(4):1203–1207

    Article  PubMed  CAS  Google Scholar 

  29. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2):138–146

    Article  PubMed  CAS  Google Scholar 

  30. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. J Am Med Assoc 294(1):47–55

    Article  CAS  Google Scholar 

  31. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S et al (1998) Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58(17):3761–3764

    PubMed  CAS  Google Scholar 

  32. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867

    Article  PubMed  CAS  Google Scholar 

  33. Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM et al (2006) Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354(8):795–808

    Article  PubMed  CAS  Google Scholar 

  34. Brogger J, Bakke P, Eide GE, Gulsvik A (2003) Contribution of follow-up of nonresponders to prevalence and risk estimates: a Norwegian respiratory health survey. Am J Epidemiol 157(6):558–566

    Article  PubMed  Google Scholar 

  35. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martin-Mola E et al (2007) Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 56(2):555–567

    Article  PubMed  CAS  Google Scholar 

  36. McAlindon TE, LaValley MP, Gulin JP, Felson DT (2000) Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283(11):1469–1475

    Article  PubMed  CAS  Google Scholar 

  37. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N et al (2008) OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16(2):137–162

    Article  PubMed  CAS  Google Scholar 

  38. Product review of joint health supplements with glucosamine, chondroitin, and/or MSM. Updated 8/2/2010–11/30/2010. Available from ConsumerLab.com

  39. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work is supported in part by grants R25-CA94880, R01-CA142545, and K05-CA154337 from the National Institutes of Health, National Cancer Institute. Dr. Slatore’s work on this project was supported with resources and the use of facilities at the Portland VA Medical Center.

Author information

Authors and Affiliations

  1. Cancer Prevention Unit, The Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-B402, Seattle, WA, 98109-1024, USA

    Theodore M. Brasky, Johanna W. Lampe & Emily White

  2. Department of Epidemiology, University of Washington, Seattle, WA, USA

    Theodore M. Brasky, Johanna W. Lampe & Emily White

  3. Health Services Research and Development, Portland Veterans Affairs Medical Center, Portland, OR, USA

    Christopher G. Slatore

  4. Division of Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA

    Christopher G. Slatore

Authors
  1. Theodore M. Brasky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johanna W. Lampe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher G. Slatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emily White
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodore M. Brasky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brasky, T.M., Lampe, J.W., Slatore, C.G. et al. Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control 22, 1333–1342 (2011). https://doi.org/10.1007/s10552-011-9806-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-011-9806-8

Keywords

Search

Navigation